[go: up one dir, main page]

MX2023012960A - Proceso para preparar inhibidores de btk. - Google Patents

Proceso para preparar inhibidores de btk.

Info

Publication number
MX2023012960A
MX2023012960A MX2023012960A MX2023012960A MX2023012960A MX 2023012960 A MX2023012960 A MX 2023012960A MX 2023012960 A MX2023012960 A MX 2023012960A MX 2023012960 A MX2023012960 A MX 2023012960A MX 2023012960 A MX2023012960 A MX 2023012960A
Authority
MX
Mexico
Prior art keywords
btk inhibitors
preparing
methyl
preparing btk
etrahydro
Prior art date
Application number
MX2023012960A
Other languages
English (en)
Inventor
Serena Maria Fantasia
Stephan Bachmann
Kurt Puentener
Ursula Hoffmann
Paolo Tosatti
Alec Fettes
Christian Oliver Kappe
Jason Douglas Williams
Lukas Chytil
Rene Lebl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2023012960A publication Critical patent/MX2023012960A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/18—Carbon
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/54—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36
    • B01J23/56—Platinum group metals
    • B01J23/64—Platinum group metals with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
    • B01J23/648—Vanadium, niobium or tantalum or polonium
    • B01J23/6482—Vanadium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
    • B01J31/2208—Oxygen, e.g. acetylacetonates
    • B01J31/2226—Anionic ligands, i.e. the overall ligand carries at least one formal negative charge
    • B01J31/2252—Sulfonate ligands
    • B01J31/2256—Sulfonate ligands being perfluorinated, i.e. comprising at least one perfluorinated moiety as substructure in case of polyfunctional ligands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2265—Carbenes or carbynes, i.e.(image)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B37/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving either the formation of a carbon-to-carbon bond between two carbon atoms not directly linked already or the disconnection of two directly linked carbon atoms
    • C07B37/04—Substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/04—Formation or introduction of functional groups containing nitrogen of amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B01J2231/42—Catalytic cross-coupling, i.e. connection of previously not connected C-atoms or C- and X-atoms without rearrangement
    • B01J2231/4205—C-C cross-coupling, e.g. metal catalyzed or Friedel-Crafts type
    • B01J2231/4211—Suzuki-type, i.e. RY + R'B(OR)2, in which R, R' are optionally substituted alkyl, alkenyl, aryl, acyl and Y is the leaving group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Health & Medical Sciences (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Chemistry (AREA)

Abstract

Se proporcionan métodos para preparar el compuesto inhibidor de la tirosina quinasa de Bruton ("BTK") 2-{3'-hidroximetil-1-metil-5 -[5-((S)-2-metil-4-oxetan-3-il-piperazin-1-il)-piridin-2-ilamino] -6-oxo-1,6-dihidro-[3,4']bipiridinil-2'-il}-7,7-dimetil-3,4,7,8-t etrahidro-2H,6H-ciclopenta[4,5]pirrolo[1,2-a]pirazin-1-ona.
MX2023012960A 2021-05-05 2022-05-03 Proceso para preparar inhibidores de btk. MX2023012960A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21172180 2021-05-05
EP21181156 2021-06-23
PCT/EP2022/061741 WO2022233801A1 (en) 2021-05-05 2022-05-03 Process for preparing btk inhibitors

Publications (1)

Publication Number Publication Date
MX2023012960A true MX2023012960A (es) 2023-11-16

Family

ID=81927751

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012960A MX2023012960A (es) 2021-05-05 2022-05-03 Proceso para preparar inhibidores de btk.

Country Status (14)

Country Link
US (2) US12084454B2 (es)
EP (2) EP4334311B1 (es)
KR (1) KR20240004918A (es)
AR (1) AR125788A1 (es)
AU (1) AU2022269229B2 (es)
CA (1) CA3216857A1 (es)
ES (1) ES3012969T3 (es)
HR (1) HRP20250178T1 (es)
HU (1) HUE070539T2 (es)
IL (1) IL307819A (es)
MX (1) MX2023012960A (es)
PL (1) PL4334311T3 (es)
TW (2) TWI869230B (es)
WO (1) WO2022233801A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026017823A1 (en) 2024-07-18 2026-01-22 F. Hoffmann-La Roche Ag Process for preparing btk inhibitor intermediates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
PL3154689T3 (pl) * 2014-06-12 2021-07-12 Johnson Matthey Public Limited Company Kompleksy
DE102016113090A1 (de) 2016-07-15 2018-01-18 Wavepack Gmbh Vorrichtung zum Verschließen von Versandverpackungen
MX386843B (es) 2016-12-15 2025-03-19 Hoffmann La Roche Proceso para preparar inhibidores de tirosina cinasa de bruton (btk)
JP7152403B2 (ja) 2016-12-19 2022-10-12 エフ．ホフマン－ラ ロシュ アーゲー 窒素含有生体ポリマー系触媒、それらの調製方法、ならびに水素化法、還元的脱ハロゲン、および酸化におけるその使用
CN115715291B (zh) 2020-06-18 2025-04-29 上海华汇拓医药科技有限公司 布鲁顿酪氨酸激酶抑制剂及其制备方法

Also Published As

Publication number Publication date
US20250084086A1 (en) 2025-03-13
CA3216857A1 (en) 2022-11-10
TW202428581A (zh) 2024-07-16
EP4545537A2 (en) 2025-04-30
AR125788A1 (es) 2023-08-16
JP2024517004A (ja) 2024-04-18
HUE070539T2 (hu) 2025-06-28
EP4334311B1 (en) 2024-12-25
US20240132508A1 (en) 2024-04-25
AU2022269229A1 (en) 2023-10-12
WO2022233801A1 (en) 2022-11-10
HRP20250178T1 (hr) 2025-04-11
US12084454B2 (en) 2024-09-10
EP4334311C0 (en) 2024-12-25
EP4545537A3 (en) 2025-07-16
TWI869230B (zh) 2025-01-01
EP4334311A1 (en) 2024-03-13
TW202304923A (zh) 2023-02-01
PL4334311T3 (pl) 2025-04-07
IL307819A (en) 2023-12-01
KR20240004918A (ko) 2024-01-11
AU2022269229B2 (en) 2025-02-06
TWI838741B (zh) 2024-04-11
ES3012969T3 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
MX2020012097A (es) Proceso para preparar inhibidores de tirosina cinasa de bruton (btk).
MX2023012960A (es) Proceso para preparar inhibidores de btk.
PH12021552863A1 (en) Condensed tricyclic pyrroles as alpha-1 antitrypsin modulators
ATE479687T1 (de) Kinaseinhibitoren
MX2007001289A (es) Piridinas condensadas como inhibidores de cinasa.
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
MX2018008754A (es) Composiciones de forma de dosificacion que comprenden un inhibidor de tirosina cinasa de bruton.
MY204421A (en) Pyruvate kinase activators for use in treating blood disorders
ZA202205900B (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
MY146989A (en) Kinase inhibitors
MX2010009458A (es) Derivados biciclicos heterociclicos o espirobiciclicos heterociclicos enlazados, de pirazolo[1,5-a]pirimidinas, procedimientos para su preparacion y usos de los mismos.
DOP2003000561A (es) 2-(piridin-2-ilamino)-pirido [2, 3-d] pirimindin-7-onas
UY29183A1 (es) Formulaciones
CL2011002956A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak1); composicion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, una enfermedad inflamatoria o rechazo de trasplante de organos.
PE20161388A1 (es) Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos
WO2007023110A3 (en) P38 map kinase inhibitors and methods for using the same
CR6736A (es) 5-alquilpirido[2,3-d[ piridinas como inhibidores de tirosina kinasa
TN2011000220A1 (en) Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
PE20080974A1 (es) Nuevas pirozolopirimidinas como inhibidores de quinasa dependientes de ciclina
CL2011001947A1 (es) Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular.
WO2006065820A3 (en) Pyrimidine inhibitors of erk protein kinase and uses therof
DOP2009000073A (es) Inhibidores de cinasa que catalizan la transferencia de fosforilo y/o que enlazan nucleótidos atp/gtp.
AU2017319080A1 (en) Pyrazolo[1,5-a]pyrimidine compound
WO2007120333A3 (en) Tetracyclic kinase inhibitors
ECSP066768A (es) Procedimiento para la preparacion de compuestos triazol sustituidos